secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0001628280-24-042266
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus divests Advanced Rehabilitation business to Accelmed for up to $45M
-----------------------------------------------------------------------------

- Total cash consideration of $45M: $25M at close plus up to $20M in earn-outs.
- Net proceeds of ~$20M after fees and expenses will be used to repay existing debt.
- Divestiture reduces annual revenue by ~$50M and annual Adj. EBITDA by ~$6M.
- Transaction expected to close in Q4 2024, subject to customary conditions.
- Bioventus to focus on core business and improve liquidity with the sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024042266/0001628280-24-042266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024042266/bvs-20240930.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-042266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer